Vor Biopharma Inc. Common Stock
VORVor Biopharma Inc. (VOR) is a biotechnology company focused on developing targeted therapies for cancer using cell engineering technologies. The company aims to create treatments that selectively eliminate cancer cells while preserving healthy cells, leveraging its proprietary gene-editing platforms. Founded to address challenges in oncology, Vor Biopharma emphasizes precision medicine approaches to improve patient outcomes.
Company News
Vor Biopharma is conducting a public offering of 10 million shares at $10 per share, expecting to raise $100 million. The offering includes an option for underwriters to purchase an additional 1.5 million shares.
Telitacicept demonstrated a 55% reduction in proteinuria and statistically significant improvements in kidney function during a Phase 3 clinical trial for IgA Nephropathy in China, with a favorable safety profile.
Vor Bio granted stock options and restricted stock units to 20 newly hired employees on October 15, 2025, with options vesting over a four-year period and an exercise price of $30.22 per share.
Vor Bio granted stock options and restricted stock units to seven newly hired employees under their 2023 Inducement Plan, with options vesting over a four-year period.
Vor Bio has entered into a securities purchase agreement for a private placement financing expected to raise approximately $175 million through the issuance of prefunded warrants, with participation from several investment firms.
